Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.51 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213826 | 1.00 | GRIK1 (0.51) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL5557810 | 0.98 | CA2 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL5557476 | 0.93 | CA2 (0.57) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL10066601 | 0.88 | GRIK1 (0.50) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL27489586 | 0.88 | NAAA (0.55) | GRIK1GRIK2SLC1A2SLC1A1CA2 | |
| SCHEMBL6870808 | 0.88 | CPB2 (0.50) | GRIK1GRIK2CA2GPR84FFAR1 | |
| SCHEMBL6870363 | 0.88 | CPB2 (0.50) | GRIK1GRIK2CA2GPR84FFAR1 | |
| SCHEMBL6863350 | 0.88 | CPB2 (0.50) | GRIK1GRIK2CA2GPR84FFAR1 | |
| SCHEMBL13278549 | 0.88 | CPB2 (0.50) | GRIK1GRIK2CA2GPR84FFAR1 | |
| SCHEMBL1260227 | 0.88 | CPB2 (0.50) | GRIK1GRIK2CA2GPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623921-A | Preparation method of 1, 2-dioleate glyceride | 南京威尔生物科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-107802623-B | Difluorolactam compositions for EP 4-mediated bone-related diseases and disorders | 开曼化学股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106748951-B | Difluorolactam compounds as EP4 receptor selective agonists for use in the treatment of EP4 mediated diseases and conditions | 开曼化学股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3176162-B1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-4461835-A | RESOLVING ARYLOXY-A-ALKYL ESTERS TO MAKE VITAMIN E INTERMEDIATES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1984-07-24 | — | — | US | disclosed |
| US-4435329-A | ANTIHYPERTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| EP-0010347-B1 | NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1983-11-09 | — | — | EP | disclosed |
| EP-0089769-A1 | 9-Substituted carbacyclin analogues | THE UPJOHN COMPANY (US) | 1983-09-28 | — | — | EP | disclosed |
| EP-0086611-A1 | 9-Substituted carbacyclin analogues | THE UPJOHN COMPANY (US) | 1983-08-24 | — | — | EP | disclosed |
| EP-0002590-B1 | NOVEL PROSTAGLANDIN COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN CYANAMID COMPANY (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4226775-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| EP-0010347-A1 | Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
| EP-0002590-A1 | Novel prostaglandin compounds, processes for the preparation thereof and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
| US-4001306-A | INHIBITION OF PLATELET AGGREGATION; NASAL PATENCY, LABOR INDUCEMENT, CONTROLLING BLOOD PRESSURE | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556862-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | GRIK1 657/4885GRIK2 843/4885SLC1A2 1462/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | GRIK1 657/4885GRIK2 843/4885SLC1A2 1462/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | GRIK1 657/4885GRIK2 843/4885SLC1A2 1462/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | GRIK1 657/4885GRIK2 843/4885SLC1A2 1462/4885 |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | GRIK1 657/4885GRIK2 843/4885SLC1A2 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.